Esperion
The Lipid Management Company

Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ESPR	
Last Trade:	34.77
Trade Time:	2:20 PM ET Mar 30, 2017
Change:	-0.03 (-0.072%)
Day Range	33.98 - 36.18
52-Week Range	9.40 - 48.21
Volume	1,414,300

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion Therapeutics is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly".

… (more)

Stock Performance



Press Releases [View all]

Mar 28, 2017
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference

Mar 20, 2017
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid

Mar 7, 2017
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin

Mar 6, 2017
Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session

Feb 22, 2017
Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results

Upcoming Events [View all]

Apr 4, 2017 1:40 PM ET
16th Annual Needham Healthcare Conference

Apr 17, 2017 8:00 AM ET
2017 Annual Meeting of Stockholders

Financials [View all]

Fourth Quarter Financial Results

Feb 22, 2017
Annual Report (10-K)

Mar 6, 2017
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 4, 2016
Quarterly Report (10-Q)